Licensed providers. In-home visits in Las Vegas, North Las Vegas and Brooklyn, NY.
(718) 218-4791info@briyahealth.comA research-based guide to tirzepatide, sold as Mounjaro and Zepbound: how the dual GIP and GLP-1 mechanism works, what the SURPASS and SURMOUNT trials found, side effects, FDA warnings, dosing and the open questions that remain.
Medically reviewed by Jonathan Paul Navar, MD, and David Kotlarsky, PA-C, with the Briya Health medical team.
No. Ozempic contains semaglutide, a different molecule that activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors, which is why trial results differ between the two.
In every major weight trial, tirzepatide was studied alongside a reduced-calorie diet and increased physical activity, so the published results describe the drug combined with those changes, not the drug alone. Because appetite falls, total intake usually drops on its own; the practical emphasis in clinical guidance is on eating enough protein, staying hydrated and choosing smaller, lower-fat meals that are easier to tolerate.
According to the FDA label, a missed dose should be taken as soon as possible within 4 days (96 hours) of the scheduled time. If more than 4 days have passed, the missed dose is skipped and the next dose is taken on the regular day. Two doses should always be at least 3 days (72 hours) apart. The weekly injection day can be changed as long as that 3-day gap is kept.
Yes. It's separately approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition, regardless of diabetes status.
Monitoring is typically most frequent during the dose-escalation phase, when side effects are most likely. Common checks include weight, blood pressure, heart rate, gastrointestinal symptoms and hydration, blood sugar and HbA1c in people with diabetes, kidney function when vomiting or diarrhea is significant, and a review of other medications such as insulin or sulfonylureas whose doses may need lowering.
Tirzepatide is a prescription-only medicine. Before prescribing, a licensed clinician reviews medical history and current medications and checks for contraindications, chiefly a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 and a prior serious allergic reaction to tirzepatide. Mounjaro is prescribed for type 2 diabetes; Zepbound for chronic weight management or obstructive sleep apnea with obesity.
Unused tirzepatide is stored in the refrigerator at 36 to 46°F (2 to 8°C) and must not be frozen. If needed, single-dose pens and single-dose vials can be kept unrefrigerated at up to 86°F (30°C) for up to 21 days. Multi-dose vials and the KwikPen have their own in-use time limits printed in their instructions for use. All presentations should be kept in the original carton to protect them from light.
It's generally discouraged. Alcohol can independently irritate the stomach and pancreas, compounding tirzepatide's own gastrointestinal effects and raising the risk of pancreatitis, one of the more serious concerns with this drug class.
It can be, but combining tirzepatide with insulin or a sulfonylurea raises the risk of low blood sugar, so your provider will often reduce the dose of those other medications when tirzepatide is added.
Yes. Because tirzepatide slows stomach emptying, it can increase the risk of food or liquid entering the lungs during anesthesia or sedation. Tell every provider involved in a procedure that you're taking it.
No, never, even if the needle is changed. Sharing an injection pen carries a real risk of transmitting bloodborne infections between users.
Eating smaller meals more frequently, avoiding greasy or heavily spiced food, and stopping before feeling completely full all tend to help. Most people find nausea eases substantially within the first few weeks at a given dose.
Plateaus happen as the body's metabolic set point resists further loss. Talk to your provider rather than adjusting on your own — they may reassess your dose, nutrition plan, or activity level to help move past it.
Yes, and it's actively encouraged, particularly resistance training. Because rapid weight loss can affect muscle as well as fat, staying active helps protect lean muscle mass throughout treatment.
Not as an equivalent. Compounding copies of tirzepatide was broadly allowed only while it was on the FDA drug shortage list. The FDA declared the shortage resolved on October 2, 2024, confirmed that decision on December 19, 2024, and ended the shortage exemptions on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. Compounded products are not FDA-approved and do not undergo the FDA's review of safety, effectiveness and manufacturing quality.
The longest controlled data come from SURMOUNT-1, where 1,032 adults with prediabetes and obesity stayed on treatment for 176 weeks, about three and a half years. Weight loss was maintained (19.7% on 15 mg by the treatment-regimen analysis) and no new safety signals were reported. Data beyond that period come from ongoing studies and routine safety surveillance rather than completed randomized trials.
No. The Zepbound label states that tirzepatide may cause fetal harm and that it should be discontinued when pregnancy is recognized, based on animal studies. Weight loss offers no benefit during pregnancy. Anyone planning pregnancy should discuss timing with their clinician, and people using oral contraceptives need a non-oral or added barrier method for 4 weeks after starting and after each dose increase.
The abdomen, thigh, or upper arm. Rotating between sites each week, and within a general area, helps reduce injection-site reactions like redness or irritation building up in one spot.
Contact your provider right away. Watch for severe nausea, vomiting, or, if you're also on insulin or a sulfonylurea, symptoms of low blood sugar like shakiness, sweating, or confusion.
Tirzepatide shouldn't be combined with other tirzepatide products or any other GLP-1 receptor agonist. Any other weight-loss medication or supplement should be reviewed with your provider before combining it with tirzepatide.
Yes, both contain the identical active ingredient, tirzepatide. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management and sleep apnea — the same drug marketed under two names for two indications.
Baseline blood sugar and kidney function are common starting points, often alongside a broader metabolic panel. Your provider will tailor this to your personal health history.
Population studies found no clinically meaningful difference in how the drug behaves across kidney and liver function levels, so a standard dose adjustment usually isn't needed. That said, severe cases warrant closer monitoring, since dehydration from GI side effects can strain kidney function further.
Shakiness, sweating, confusion, dizziness, a fast heartbeat, and unusual hunger or fatigue. Tirzepatide alone rarely causes this, but the risk rises meaningfully when combined with insulin or certain other diabetes medications.
Hair loss was reported in about 4 to 5% of people on Zepbound in the weight trials compared with 1% on placebo, according to the label. It is usually telogen effluvium, a temporary shedding pattern that follows rapid weight loss, surgery or illness, and it generally settles within months once weight stabilizes. Adequate protein, iron and overall nutrition are the usual focus.
No. It isn't a controlled substance and doesn't produce chemical dependence. Stopping doesn't cause withdrawal symptoms, though appetite and weight often trend back toward baseline over time without the medication.
Zepbound, the weight management brand, is approved only for adults. In February 2026 the FDA approved Mounjaro for children aged 10 and older with type 2 diabetes, at doses up to 10 mg, based on the SURPASS-PEDS trial. Tirzepatide is not approved for weight management in people under 18, and trials in adolescents with obesity are ongoing.
There's no pharmacological requirement to taper the dose down gradually before stopping. That said, talk with your provider about your reasons for stopping and what to expect afterward, since weight and appetite often trend back toward baseline once treatment ends.
It can, since the body doesn't always distinguish between fat and muscle when calorie intake drops sharply. This is a general risk of rapid weight loss from any cause, which is why adequate protein and resistance training are standard parts of care during treatment.
Data on tirzepatide use during breastfeeding is limited, and it isn't currently recommended. Discuss your specific situation and timing with your provider.
In SURMOUNT-1, adults without diabetes lost an average of 15.0%, 19.5% and 20.9% of their body weight on the 5, 10 and 15 mg doses over 72 weeks, compared with 3.1% on placebo. People with type 2 diabetes lost less: 12.8% to 14.7% in SURMOUNT-2. Individual results vary widely, and averages in routine care are usually lower than in trials.
Appetite often decreases within the first few weeks, and blood sugar starts to improve early in people with diabetes. The starting 2.5 mg dose is intended to help the body adjust rather than to produce weight loss, so most weight change occurs after the dose is increased. In the trials, weight loss continued for about a year before leveling off.
Usually, at least in part. In SURMOUNT-4, people who lost about 21% over 36 weeks and were then switched to placebo regained 14% of their body weight over the following year, while those who continued lost a further 5.5%. Maintaining changes in diet and activity helps, but trial evidence shows most of the effect depends on continued treatment.
In people with type 2 diabetes and heart disease, the SURPASS-CVOT trial found tirzepatide at least as protective as dulaglutide, a GLP-1 drug already shown to lower cardiovascular events, with a hazard ratio of 0.92 for heart attack, stroke or cardiovascular death and 16% fewer deaths from any cause. A trial in people with obesity but without diabetes, SURMOUNT-MMO, has not yet reported.
Yes. In December 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, at maintenance doses of 10 or 15 mg. In the SURMOUNT-OSA trials, breathing disruptions per hour fell by about 51% to 59%, and up to about half of participants reached criteria for disease resolution.
In SURMOUNT-5, the only head-to-head trial in obesity, adults without diabetes lost 20.2% of body weight on tirzepatide compared with 13.7% on semaglutide 2.4 mg (Wegovy) over 72 weeks. Side effects were similar in type. Semaglutide has cardiovascular outcome data in people without diabetes from the SELECT trial, which tirzepatide does not yet have.
In the three-year SURMOUNT-1 extension in 1,032 adults with prediabetes and obesity, 1.2% of people on tirzepatide developed type 2 diabetes compared with 12.6% on placebo, a 94% reduction in risk. After 17 weeks off treatment, the figures were 2.4% and 13.7%. Tirzepatide is not approved specifically for diabetes prevention.
Mounjaro and Zepbound carry a boxed warning for thyroid C-cell tumors, based on rodent studies. It is unknown whether tirzepatide causes these tumors, including medullary thyroid carcinoma, in humans. It must not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Yes, slightly. According to the Zepbound label, average resting heart rate rose by 1 to 3 beats per minute compared with no increase on placebo. This is a known effect of the GLP-1 medication class. A persistent, unexplained fast heartbeat is worth reporting to a clinician.
Both are listed warnings. In the weight management trials, acute pancreatitis occurred in 0.2% of people on tirzepatide and 0.2% on placebo, while gallbladder inflammation occurred in 0.7% compared with 0.2%, and gallstones in 1.1% compared with 1%. Severe, persistent abdominal pain, with or without vomiting, needs prompt medical assessment.
Tirzepatide is an FDA-approved medication that activates two hormone receptors the body already uses to regulate blood sugar and appetite: GLP-1 and GIP. Together, these signals slow digestion, increase feelings of fullness, reduce food intake and improve how the body responds to insulin. It is given as a once-weekly injection, and the dose is increased gradually over several months to reduce gastrointestinal side effects such as nausea, which are most common early in treatment and after each dose increase. In clinical trials it was always studied alongside diet and activity changes, and its effects on appetite and weight fade after it is stopped.
Safe use of tirzepatide starts with screening for reasons not to use it, including a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, severe gastrointestinal disease such as gastroparesis, pregnancy or plans for pregnancy, and diabetic retinopathy. During treatment, monitoring usually covers weight, blood pressure, heart rate, gastrointestinal symptoms and hydration, and, in people with diabetes, blood sugar and HbA1c, with doses of insulin or sulfonylureas adjusted to limit hypoglycemia. Most monitoring is concentrated in the first several months, while the dose is being increased.
Many people notice reduced appetite within the first few weeks, while weight change builds gradually over months. In SURMOUNT-1, average weight loss at 72 weeks was 15.0%, 19.5% and 20.9% on the 5, 10 and 15 mg doses, compared with 3.1% on placebo, and weight loss slowed toward a plateau over the second half of the trial. Individual results vary widely: some people lose far more than average, while roughly one in ten on the highest doses lose less than 5%. Protein intake and resistance training are commonly emphasized during treatment because they help preserve muscle mass while weight falls.
Unused tirzepatide is stored in the refrigerator at 36 to 46°F (2 to 8°C) and should never be frozen; product that has frozen must be discarded. Single-dose pens and single-dose vials may be kept unrefrigerated at up to 86°F (30°C) for up to 21 days, while multi-dose vials and KwikPens follow the in-use limits in their own instructions. Pens are for single-patient use only and should never be shared, even with the needle changed, since sharing an injection device carries a real risk of transmitting bloodborne infection.
Alcohol is generally discouraged during treatment. It can independently irritate the stomach and pancreas, compounding tirzepatide's own gastrointestinal effects and raising the risk of pancreatitis, one of the rarer but more serious concerns with this drug class. Nausea, when it occurs, typically responds well to practical adjustments: eating smaller meals more frequently, avoiding greasy, fried, or heavily spiced food, and stopping eating before feeling completely full. Most people find these effects ease substantially within the first few weeks at a given dose and often flare briefly again after each increase.
Tirzepatide, marketed as Mounjaro and Zepbound, was the first medication approved to work as a dual agonist, activating both the GIP and GLP-1 receptors rather than just one. Eli Lilly developed it for type 2 diabetes, and the FDA approved it as Mounjaro on May 13, 2022, based on the SURPASS trial program. Its weight-loss effects were large enough that Lilly pursued a separate approval for chronic weight management, granted as Zepbound on November 8, 2023, for adults with obesity, or with overweight plus at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. On December 20, 2024, Zepbound became the first medication approved for moderate-to-severe obstructive sleep apnea in adults with obesity, and in February 2026 Mounjaro's approval was extended to children aged 10 and older with type 2 diabetes. The European Medicines Agency has approved Mounjaro for both type 2 diabetes and weight management.
Mounjaro and Zepbound contain the same molecule, tirzepatide, made by the same company, in the same six dose strengths from 2.5 mg to 15 mg. The two brand names exist because the FDA approves a medicine for specific uses, and Eli Lilly sought the diabetes and weight management approvals separately, with different labels, different trial programs behind them and, often, different insurance treatment.
Mounjaro is approved to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise, and since February 2026 in children aged 10 and older with type 2 diabetes. It is not approved for type 1 diabetes. Zepbound is approved to reduce excess body weight and maintain weight reduction long term in adults with obesity (BMI of 30 or more) or overweight (BMI of 27 or more) with at least one weight-related condition, and to treat moderate-to-severe obstructive sleep apnea in adults with obesity. Both labels specify use alongside diet and physical activity.
The distinction matters mainly for coverage and prescribing. Insurers often cover Mounjaro for diabetes but restrict or exclude drugs prescribed purely for weight, and a prescription for one brand cannot simply be filled with the other. Zepbound is available in the United States as single-dose pens, single-dose vials, multi-dose vials and a KwikPen, with vials sold directly by the manufacturer at a lower cash price. Coverage rules, including in Medicare, have been changing, so the current terms of a specific plan are the only reliable guide.
Clinically, the two behave identically in adults. The titration schedule starts at 2.5 mg for four weeks and rises in 2.5 mg steps at least four weeks apart. The oral contraceptive advice, boxed warning and other precautions are the same on both labels, and neither should be combined with the other or with any other GLP-1 receptor agonist.
Trial results apply most directly to people who resemble the participants. SURMOUNT-1, the main weight management trial, enrolled adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition other than diabetes. Their average age was about 45, about two-thirds were women, average weight was about 105 kg (231 pounds) and average BMI was 38. Participants came from nine countries, and most had tried to lose weight before without lasting success.
The trials excluded several groups, which is why evidence for them is thinner. People with a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, recent heart attack or stroke, severe kidney disease in some trials, major depression or a history of suicide attempts in some trials, and people who had had bariatric surgery were generally not enrolled. Pregnant and breastfeeding women were excluded from all trials.
People with type 2 diabetes were studied separately in SURMOUNT-2 and the SURPASS program, and people with established heart disease and diabetes in SURPASS-CVOT. Older adults were included, but people over 75 were relatively few, so the balance between benefit and risks such as muscle loss is less well defined in that age group. Participants in all trials received regular visits, lifestyle counseling and supervised dose increases, which may not reflect routine care.
Real-world studies drawn from health records and insurance data now include hundreds of thousands of people taking tirzepatide. They broadly confirm the trial findings on weight loss and side effects, though average results are smaller because many people stop early, stay on lower doses or face interruptions in supply or coverage. Observational studies cannot establish cause and effect the way randomized trials do, so their findings on new benefits or harms are treated as signals to be tested rather than conclusions.
Tirzepatide is a synthetic 39-amino-acid peptide built on the structural backbone of native GIP. Two modified amino acids, inserted at specific points in the chain, protect it from the enzyme that normally breaks down GIP and GLP-1 within minutes of release into the bloodstream. A fatty acid chain attached elsewhere in the molecule lets it bind loosely to albumin, the most abundant protein in blood — this is what stretches its effective half-life to roughly five days and makes once-weekly dosing possible. It's supplied as a clear, injectable solution in pre-filled pens or vials, available in six strengths (2.5, 5, 7.5, 10, 12.5, and 15 mg), which allows the gradual, step-by-step dose increases that make the medication easier to tolerate.
Both GLP-1 and GIP are gut hormones released after eating, part of what's called the incretin effect — the reason oral glucose triggers a much bigger insulin response than glucose delivered straight into a vein. GLP-1 works by boosting insulin release when blood sugar is high, suppressing glucagon (which the liver uses to raise blood sugar), slowing digestion, and reducing appetite through receptors in the brain. GIP does something similar for insulin, but its role in appetite and fat metabolism was underappreciated for years, since its effect seemed blunted in people with diabetes. Researchers later realized that blunting was a consequence of high blood sugar itself, not a flaw in GIP — once glucose control improves, GIP's pathway re-engages, which opened the door to a medication that uses both hormones together.
What makes tirzepatide notable isn't just that it engages both receptors; it engages them unevenly. It behaves as a full, potent agonist at the GIP receptor, with an affinity similar to native GIP, but binds the GLP-1 receptor about five times more weakly than native GLP-1 and favors certain signaling pathways there. One hypothesis is that GIP activity reduces nausea signaling in the brainstem, which would allow more total metabolic effect for a given level of GI side effects, but this has not been proven in people, and tirzepatide still causes substantial nausea at higher doses. What is established is the clinical result: in head-to-head trials against semaglutide, the leading GLP-1-only medication, tirzepatide produced larger reductions in both HbA1c and body weight.
After a subcutaneous injection, tirzepatide absorbs slowly: peak blood levels are reached anywhere from 8 to 72 hours later, which produces a smooth, sustained effect rather than sharp spikes. About 99% of the drug circulates bound to albumin, which protects it from rapid breakdown and from filtration by the kidneys, giving a half-life of about five days. Because it is a peptide, it is broken down by general protein metabolism rather than the liver's cytochrome P450 enzymes, so it has little potential for the enzyme-based interactions that affect many oral drugs. Population pharmacokinetic analyses found that age, sex, race, ethnicity, kidney function, liver function and body weight do not change its behavior enough to require dose adjustments, so the same titration schedule is used for most adults.
Like any injectable protein, tirzepatide can prompt the immune system to develop antibodies against it. Across seven trials involving over 5,000 people with type 2 diabetes, roughly half developed these antibodies at some point, but very few developed the kind capable of actually blocking the drug's effect — about 2% or less. Even in that small group, the antibodies didn't measurably change how well the drug worked or how quickly the body cleared it. Some people with antibodies had a slightly higher rate of mild injection-site reactions, but nothing serious. In short: an immune response is common, but it doesn't appear to compromise the medication's effectiveness.
SURPASS is Eli Lilly's name for the series of trials that established tirzepatide's effectiveness for type 2 diabetes, testing it everywhere from first-line treatment to add-on therapy in people already on insulin. A consistent theme ran through every trial: reductions in both blood sugar and body weight far beyond what earlier medications had achieved.
In 478 adults with type 2 diabetes not controlled by diet and exercise alone, tirzepatide was tested as a standalone medication over 40 weeks. All three doses beat placebo by a wide margin: HbA1c (the standard three-month blood sugar marker) fell by 1.87 to 2.07 percentage points, compared with almost no change on placebo. Weight fell by 7.0 to 9.5 kg depending on dose. At the highest dose, 88% of participants reached an HbA1c below 7%, and about half reached a level below 5.7%, the threshold for normal glucose.
This 40-week trial compared tirzepatide directly with semaglutide 1 mg, then the highest approved diabetes dose, in 1,879 people already taking metformin. Every tirzepatide dose outperformed semaglutide on both blood sugar and weight: the 15 mg dose reduced HbA1c by 2.30 percentage points versus 1.86 for semaglutide, and weight by 11.2 kg versus 5.7 kg. The result was the first strong evidence that adding GIP activity produced more than an incremental improvement over a GLP-1-only medication, although semaglutide has since been approved at a higher 2 mg diabetes dose that was not tested here.
Later SURPASS trials tested tirzepatide against basal insulin (SURPASS-3), in a high cardiovascular-risk population (SURPASS-4), and as an add-on for people already using insulin (SURPASS-5). In each case, tirzepatide outperformed the comparator on blood sugar control while insulin-based comparators were associated with weight gain rather than loss — in SURPASS-3, for example, the 15 mg dose produced 12.9 kg of weight loss while the insulin group gained 2.3 kg. SURPASS-4 also provided an early signal that tirzepatide may help protect kidney function in people with diabetes, an effect being studied further in ongoing trials.
This trial enrolled 2,539 adults with obesity or overweight who did not have diabetes. At 72 weeks, the 15 mg dose produced average weight loss of 20.9%, compared with 3.1% on placebo, which is about 48 pounds on average. Participants who had prediabetes at the start (1,032 people) continued for 176 weeks in total. By then, weight loss on 15 mg was 19.7% (22.9% among those who stayed on treatment), and only 1.2% of people on tirzepatide had developed type 2 diabetes, compared with 12.6% on placebo, a 94% reduction in risk.
Losing weight is typically harder for people who also have type 2 diabetes. This trial tested that directly in 938 adults with both conditions, and after 72 weeks, the 15 mg dose still produced a 14.7% weight reduction versus 3.2% for placebo — meaningfully lower than the non-diabetic SURMOUNT-1 results, but still substantial. Between 79% and 83% of participants lost at least 5% of their body weight, compared to just 32% on placebo.
This trial put tirzepatide and semaglutide 2.4 mg (Wegovy) directly against each other in 751 adults with obesity but without diabetes, each at its maximum tolerated dose over 72 weeks. Tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide, and 31.6% of tirzepatide patients lost at least a quarter of their body weight, compared with 16.1% on semaglutide. Gastrointestinal side effects were common with both, and discontinuation because of gastrointestinal side effects was 2.7% with tirzepatide versus 5.6% with semaglutide.
Two SURMOUNT trials were designed to answer questions the headline trial could not: does tirzepatide add anything for people who have already lost weight through lifestyle change, and what happens when people who respond well stop taking it? Both trials changed how obesity medications are discussed, because they show weight management with these drugs behaving more like the treatment of a chronic condition than a one-time course.
SURMOUNT-3 began with a 12-week intensive lifestyle program of diet, exercise and counseling for 806 adults with obesity or overweight and no diabetes. Only people who lost at least 5% of their body weight during that phase went on to be randomized, 579 in total, to tirzepatide at the maximum tolerated dose or placebo for a further 72 weeks. From the point of randomization, the tirzepatide group lost an additional 18.4% of body weight on average, while the placebo group regained 2.5%. The trial showed that people who had already done well with lifestyle change still gained substantially from the drug, and that without it, some regain was the typical course even after an intensive program.
SURMOUNT-4 tested withdrawal directly. All 783 participants took tirzepatide openly for 36 weeks, titrated to 10 or 15 mg, and lost an average of 20.9%. The 670 who completed that phase were then randomized either to continue tirzepatide or to switch, without knowing it, to placebo for another 52 weeks. Those who continued lost a further 5.5%. Those switched to placebo regained 14.0% of their body weight, finishing about 9.9% below their original starting weight, which means roughly half of the lost weight had returned. About 89.5% of those who stayed on tirzepatide kept at least 80% of their initial weight loss, compared with 16.6% of those switched to placebo.
Cardiometabolic measures followed weight. In the placebo group of SURMOUNT-4, improvements in blood pressure, cholesterol and insulin levels that had appeared during the lead-in phase partly reversed as weight returned. The practical lesson drawn by most clinical guidelines is that tirzepatide treats weight while it is being taken, in the same way that blood pressure medication lowers blood pressure while it is being taken. Lower maintenance doses and gradual step-downs are being studied, but there is not yet trial evidence establishing a reliable way to stop the drug without regain.
A common concern with any large weight loss is how much of it comes from muscle rather than fat. SURMOUNT-1 included a substudy of 160 participants who had dual-energy X-ray absorptiometry (DXA) scans, the standard research method for measuring body composition. At 72 weeks, fat mass had fallen by 33.9% on tirzepatide compared with 8.2% on placebo, while lean mass had fallen by 10.9% compared with 2.6%. Put another way, roughly three-quarters of the weight lost was fat and about one-quarter was lean mass.
That ratio is similar to what is seen with calorie restriction and with bariatric surgery. Losing some lean mass during weight loss is expected, partly because a lighter body needs less muscle to carry it and partly because lean mass as measured by DXA includes water, organ tissue and connective tissue as well as skeletal muscle. Because fat fell proportionally more than lean mass, the share of the body made up of lean tissue actually increased in the tirzepatide group.
This does not mean muscle loss is unimportant. For older adults, people with low muscle mass at baseline and anyone losing weight very quickly, preserving strength matters for mobility, metabolic health and fall risk. The trials did not specifically test strategies to protect muscle, so the recommendations come from the broader weight loss literature: adequate protein, commonly around 1.2 to 1.6 grams per kilogram of target body weight per day unless kidney disease requires otherwise; resistance training at least two to three times a week; and attention to overall nutrition when appetite is very low.
Newer drugs designed to preserve muscle during GLP-1-based weight loss are in development, and several trials are combining tirzepatide with agents that act on muscle growth pathways. Until those studies report, the most reliable tools for protecting lean mass remain exercise and nutrition, used alongside the medication rather than replaced by it.
About 40% of the participants in SURMOUNT-1 had prediabetes when they entered the trial, meaning blood sugar levels above normal but below the threshold for type 2 diabetes. Those 1,032 people continued in the trial for 176 weeks in total, making this the longest randomized, placebo-controlled experience with tirzepatide for weight management, and the results were published in the New England Journal of Medicine.
At 176 weeks, average weight loss was 12.3%, 18.7% and 19.7% on the 5, 10 and 15 mg doses, compared with 1.3% on placebo, counting everyone who was randomized. Among people who stayed on treatment, the figures were 15.4%, 19.9% and 22.9%, compared with 2.1% on placebo. Only 1.2% of those on tirzepatide were diagnosed with type 2 diabetes over the three years, compared with 12.6% on placebo, a hazard ratio of 0.06, or a 94% reduction in risk.
The trial then stopped treatment for 17 weeks to see whether the benefit persisted. After that off-treatment period, 2.4% of the tirzepatide group had developed diabetes compared with 13.7% of the placebo group. The gap remained large, but the proportion developing diabetes in the former tirzepatide group had doubled in just four months, and weight had begun to return, which is consistent with SURMOUNT-4's finding that the drug's effects depend on continued use.
Tirzepatide is not approved specifically for diabetes prevention, and people with prediabetes qualify for Zepbound only if they meet its weight-based criteria. Lifestyle programs such as the Diabetes Prevention Program remain the established first step, with a 58% reduction in diabetes incidence in their original trial, though the magnitude of the tirzepatide effect is considerably larger.
Tirzepatide trial results are usually reported with two different figures for the same dose, and knowing the difference prevents a lot of confusion. In SURMOUNT-1, for example, the 15 mg dose produced average weight loss of 20.9% by one analysis and 22.5% by the other. Both are correct, because they answer different questions.
The treatment-regimen estimand counts everyone who was randomized, including people who stopped the drug, missed doses or switched to other treatment. It answers the question of what happens to a group of people who are prescribed the medication. The efficacy estimand estimates what would happen if everyone took the drug as intended for the whole trial. It answers the question of how well the drug works in people who stay on it. The gap between the two widens as more people stop treatment.
Several other details change what a figure means. Weight loss is reported as a percentage of starting body weight, so a 20% loss means roughly 20 kg for someone starting at 100 kg and 30 kg for someone starting at 150 kg. People with type 2 diabetes consistently lose less than people without it, as SURMOUNT-2 showed. Trial participants received regular visits, dietary counseling and free medication, conditions that usually produce better adherence than routine care. Real-world studies of tirzepatide generally report somewhat smaller average weight loss than the trials, largely because many people stop or never reach the higher doses.
A useful habit when reading any claim about tirzepatide is to ask four questions: which trial, which dose, how many weeks, and which analysis. A claim that tirzepatide produces over 20% weight loss is accurate for the 15 mg dose at 72 weeks in adults without diabetes. Presented without those details, it describes a result that many people will not reach, and that is the most common way accurate numbers become misleading.
In two 52-week SURMOUNT-OSA trials in 469 adults with obesity, tirzepatide reduced breathing disruptions per hour (AHI) by about 51 to 59% versus 3% or less on placebo, with 18 to 20% weight loss. Up to about half reached criteria for disease resolution, compared with roughly 15% on placebo. It is not a substitute for CPAP where CPAP is still needed.
In the SUMMIT trial of 731 adults with obesity and heart failure with preserved ejection fraction, tirzepatide lowered the combined risk of cardiovascular death or worsening heart failure by 38% (HR 0.62), driven by fewer worsening heart failure events rather than fewer deaths, and improved symptoms and walking distance. It is not FDA-approved for this use.
In the phase 2 SYNERGY-NASH trial of 190 adults with MASH and liver fibrosis, 44 to 62% of those on tirzepatide had MASH resolve without worsening fibrosis at 52 weeks, versus 10% on placebo. Phase 3 trials are ongoing, and tirzepatide is not approved for MASH.
For any diabetes medication, the question regulators and cardiologists care about most is whether it reduces heart attacks, strokes and deaths. SURPASS-CVOT answered that for tirzepatide. It randomized 13,165 adults with type 2 diabetes and established atherosclerotic cardiovascular disease to tirzepatide up to 15 mg or dulaglutide 1.5 mg, a GLP-1 medication that had already been shown to reduce cardiovascular events in the REWIND trial. Participants were followed for a median of about four years, and the results were published in the New England Journal of Medicine in December 2025.
The primary endpoint was major adverse cardiovascular events: cardiovascular death, heart attack or stroke. It occurred in about 12% of people on tirzepatide and 13% on dulaglutide, a hazard ratio of 0.92. That result met the trial's test for noninferiority, meaning tirzepatide was at least as protective as dulaglutide, but it did not meet the statistical threshold for superiority. Deaths from any cause were lower on tirzepatide, 8.6% compared with 10.2%, a hazard ratio of 0.84, and a composite kidney endpoint occurred in 4.9% compared with 6.1%.
Because dulaglutide is itself an active, protective drug, the trial was a demanding comparison. Comparing against an active GLP-1 drug, rather than placebo, reflected the fact that proven cardioprotective treatments already existed for this population. The finding places tirzepatide at least on a par with established cardioprotective GLP-1 medications for people with diabetes and heart disease, with signals of additional benefit on death and kidney outcomes that come from secondary analyses and need confirmation.
Gastrointestinal side effects were more common with tirzepatide, and 13.2% of people stopped it because of adverse events compared with 10.1% on dulaglutide. SURPASS-CVOT enrolled only people with diabetes. A separate outcomes trial in people with obesity but without diabetes, SURMOUNT-MMO, is testing whether tirzepatide reduces cardiovascular events in that group, and its results are needed before cardiovascular benefit can be claimed for weight management use.
Heart failure with preserved ejection fraction, or HFpEF, is a form of heart failure in which the heart pumps normally but is stiff and fills poorly. It is strongly linked to obesity, and until recently few treatments improved it. The SUMMIT trial randomized 731 adults with HFpEF and a BMI of 30 or higher to tirzepatide up to 15 mg or placebo, with a median follow-up of about two years.
The primary outcome combined cardiovascular death with worsening heart failure events such as hospitalization or urgent intravenous treatment. It occurred in 36 people on tirzepatide and 56 on placebo, a hazard ratio of 0.62, meaning a 38% lower risk. The benefit came from fewer worsening heart failure events; there was no significant difference in cardiovascular deaths, which were few in both groups. At 52 weeks, tirzepatide also produced larger improvements in the Kansas City Cardiomyopathy Questionnaire, a standard measure of symptoms and physical limitation, and in six-minute walking distance.
Body weight fell by 11.6% more on tirzepatide than on placebo, and markers of inflammation such as high-sensitivity C-reactive protein also fell. In a cardiac MRI substudy of 106 participants, heart muscle mass decreased by about 11 grams and fat around the heart by about 45 milliliters relative to placebo, supporting the idea that removing excess fat around and within the heart improves how it fills.
SUMMIT was relatively small for an outcomes trial and the number of events was modest, so the estimate of benefit is less precise than in large cardiovascular trials. Heart failure is not an FDA-approved indication on the current Zepbound label. Semaglutide has shown similar symptom benefits in the STEP-HFpEF trials. For people with obesity-related HFpEF, these results have shifted clinical thinking toward treating obesity as part of heart failure care, alongside SGLT2 inhibitors and diuretics.
Obstructive sleep apnea occurs when the upper airway repeatedly narrows or closes during sleep, interrupting breathing and oxygen supply. Excess weight is the strongest modifiable risk factor. Its severity is measured by the apnea-hypopnea index, or AHI, the number of breathing disruptions per hour of sleep: 15 to 29 is moderate and 30 or more is severe. The standard treatment is positive airway pressure (PAP), such as CPAP, which works well but which many people find hard to use every night.
SURMOUNT-OSA consisted of two 52-week trials in 469 adults with obesity and moderate-to-severe sleep apnea. Study 1 enrolled people not using PAP; study 2 enrolled people who were using PAP and continued it. In study 1, AHI fell by 25.3 events per hour on tirzepatide compared with 5.3 on placebo, a reduction of about 51% versus 3%. In study 2, it fell by 29.3 compared with 5.5 events per hour, about 59% versus 3%. These are treatment-regimen figures; efficacy estimand reductions were about 55% and 63%.
Disease resolution, defined as an AHI below 5, or 5 to 14 with little daytime sleepiness, was reached by 42% and 50% of people on tirzepatide in the two studies, compared with 16% and 14% on placebo. Weight fell by about 18% and 20% respectively. Blood pressure, measures of oxygen levels during sleep, inflammation markers and patient-reported sleepiness also improved. The most common side effects were diarrhea, nausea, vomiting and constipation, consistent with other tirzepatide trials.
On December 20, 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first medication approved for the condition. The approved maintenance dose is 10 or 15 mg weekly. Roughly half of participants did not reach resolution, and sleep apnea can have causes beyond weight, such as jaw or airway anatomy. Decisions about stopping PAP are made on the basis of repeat sleep testing, not weight loss alone.
Metabolic dysfunction-associated steatotic liver disease, formerly called non-alcoholic fatty liver disease, affects roughly a third of adults worldwide. In a subset, fat accumulation leads to inflammation and cell injury, a stage called metabolic dysfunction-associated steatohepatitis (MASH), which can progress to fibrosis, cirrhosis and liver cancer. Weight loss of about 10% or more is known to improve MASH, but it is hard to achieve and sustain through lifestyle change alone.
SYNERGY-NASH was a phase 2 trial in 190 adults with biopsy-confirmed MASH and moderate or severe fibrosis (stage F2 or F3). Participants received tirzepatide 5, 10 or 15 mg or placebo for 52 weeks and then had a second liver biopsy. MASH resolved without worsening of fibrosis in 44%, 56% and 62% of the tirzepatide groups compared with 10% on placebo. Fibrosis improved by at least one stage without worsening of MASH in 55%, 51% and 51% compared with 30% on placebo, although the fibrosis result was a secondary endpoint.
The results were published in the New England Journal of Medicine in 2024. They are encouraging but come from a relatively small trial, and liver biopsy findings can vary depending on the sample taken. A larger phase 3 program is under way to confirm the effect and test whether it translates into fewer cases of cirrhosis and liver-related events.
Two drugs are now FDA-approved for MASH with moderate to advanced fibrosis: resmetirom (Rezdiffra), approved in March 2024, and semaglutide (Wegovy), approved for this use in August 2025. Tirzepatide is not approved for MASH. For people with MASH who also qualify for tirzepatide on the basis of diabetes or weight, the liver effects are a potential additional benefit rather than the reason it is prescribed.
Tirzepatide carries a boxed warning, the FDA's most serious label warning, for thyroid C-cell tumors, including a rare cancer called medullary thyroid carcinoma. This is based entirely on rodent studies where GLP-1-class drugs caused these tumors at high, sustained doses — whether the same risk applies to humans isn't known, since human thyroid cells don't share the same biology in this respect. Regardless, tirzepatide is strictly off-limits for anyone with a personal or family history of this specific cancer type or a related genetic condition called MEN 2, and providers are required to counsel patients on warning signs like a neck lump, trouble swallowing, or persistent hoarseness.
Beyond the boxed warning, several other risks require attention. Pancreatitis has been reported, though large studies haven't found a statistically significant increase in risk compared to placebo — still, the drug is stopped immediately if pancreatitis is suspected and never restarted if confirmed. Gallbladder problems, including gallstones, occur more often with tirzepatide, though this may be partly a byproduct of rapid weight loss itself rather than the drug directly. Severe or persistent vomiting and diarrhea can, in susceptible people, lead to dehydration serious enough to cause acute kidney injury, which is why staying well hydrated matters especially during the early weeks of treatment or after a dose increase. Because tirzepatide has a low intrinsic risk of causing dangerously low blood sugar on its own, that risk rises meaningfully when it's combined with insulin or certain other diabetes medications, often requiring a dose adjustment to those other drugs. People with a history of diabetic eye disease should also be monitored closely, since rapid improvement in blood sugar control can temporarily worsen existing retinopathy — a paradox seen with intensive glucose-lowering treatment generally, not something specific to this drug.
The FDA label for Zepbound pools the placebo-controlled weight management trials and lists how often each side effect occurred on 5, 10 and 15 mg compared with placebo. Nausea affected 25%, 29% and 28% of people on tirzepatide compared with 8% on placebo. Diarrhea affected 19% to 23% compared with 8%; vomiting 8% to 13% compared with 2%; and constipation 11% to 17% compared with 5%. Abdominal pain and indigestion each affected 9% to 10%.
Less common effects included injection-site reactions (6% to 8% versus 2%), fatigue (5% to 7% versus 3%), hypersensitivity reactions such as rash (5% versus 3%), belching (4% to 5% versus 1%), hair loss (4% to 5% versus 1%) and gastroesophageal reflux (4% to 5% versus 2%). Heart rate rose by an average of 1 to 3 beats per minute, with no increase on placebo. Most gastrointestinal effects were mild to moderate and occurred mainly during dose escalation, declining over time.
Permanent discontinuation because of adverse reactions occurred in 4.8%, 6.3% and 6.7% of people on 5, 10 and 15 mg compared with 3.4% on placebo. In the weight management trial in people with type 2 diabetes, hypoglycemia was reported in 4.2% on Zepbound compared with 1.3% on placebo. Acute pancreatitis was rare and occurred at similar rates on tirzepatide and placebo (0.2% each), while gallbladder inflammation (cholecystitis) occurred in 0.7% compared with 0.2%.
Side effect rates in trials depend on how quickly the dose is increased. The label's schedule of at least four weeks per step is a minimum; in practice, clinicians often stay longer at a dose if symptoms are troublesome. The most effective measures in the trials and in clinical guidance are simple: smaller meals, stopping eating at the first sign of fullness, avoiding high-fat and greasy foods, drinking fluids steadily through the day and not lying down soon after eating.
The current Zepbound label, revised in 2026, lists ten warnings and precautions. Beyond thyroid C-cell tumors, they include severe gastrointestinal adverse reactions, acute kidney injury from fluid loss, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions, hypoglycemia, diabetic retinopathy complications in people with type 2 diabetes, pulmonary aspiration during anesthesia or deep sedation, and a warning never to share a KwikPen between patients. In February 2026 the FDA removed the suicidal behavior and ideation warning that had been on the label, after an FDA review of the available data did not find an increased risk.
Severe gastrointestinal reactions, including severe vomiting and diarrhea, have been reported, and tirzepatide has not been studied in people with severe gastroparesis, so it is not recommended for them. Kidney problems in people taking tirzepatide have mostly occurred in the context of dehydration from those gastrointestinal effects, which is why fluid intake matters during dose increases and why kidney function is checked when symptoms are significant.
Pulmonary aspiration is a newer warning shared by the whole GLP-1 class. Because gastric emptying is slowed, food can remain in the stomach longer than expected, increasing the risk of stomach contents entering the lungs during anesthesia or deep sedation. Professional anesthesia societies have issued guidance on how to manage this before procedures, which may include a liquid diet the day before or other precautions, so anyone scheduled for surgery, endoscopy or sedation should tell the care team they are taking tirzepatide.
Serious allergic reactions, including anaphylaxis and angioedema, have been reported, and anyone with a previous serious reaction to tirzepatide should not use it. In people with diabetic retinopathy, rapid improvement in blood sugar can temporarily worsen the eye disease, so eye monitoring is advised. The label also notes that people with a history of pancreatitis were not studied, and that tirzepatide should be stopped promptly if pancreatitis is suspected.
Because tirzepatide slows how quickly food (and anything taken with it) leaves the stomach, it can change how well other oral medications are absorbed, an effect that is strongest right after starting treatment or increasing the dose and fades over time. For most medications this is not a meaningful concern, but it calls for extra caution with drugs where a small change in absorption matters, such as warfarin, levothyroxine or some anti-seizure medicines. The most clinically important interaction involves oral birth control. Tirzepatide can reduce how much of an oral contraceptive is absorbed, potentially making it less effective, so the FDA label advises people using oral hormonal contraception to switch to a non-oral method (patch, ring, IUD, implant or injection) or add a barrier method such as condoms for 4 weeks after starting treatment and for 4 weeks after every dose increase. Separately, the label states that tirzepatide may cause fetal harm and should be discontinued when pregnancy is recognized. Combining tirzepatide with insulin or a sulfonylurea increases the risk of hypoglycemia, and it should not be used with other GLP-1 receptor agonists.
Every tirzepatide prescription starts the same way, regardless of indication: 2.5 mg injected once weekly for the first four weeks. This starting dose isn't meant to treat anything on its own — it exists purely to let your body adjust before the medication ramps up to a level that actually affects blood sugar or weight. After those four weeks, the dose increases to 5 mg weekly, and from there it can continue rising in 2.5 mg steps (7.5, 10, 12.5, then 15 mg) at intervals of at least four weeks per step, based on how you're responding and tolerating it. For diabetes and weight management, the typical maintenance dose lands at 5, 10, or 15 mg weekly; for sleep apnea, it's 10 or 15 mg. Fifteen milligrams is the highest dose approved for any use. It's injected under the skin of the abdomen, thigh, or upper arm, with the injection site rotated each week, and can be taken at any time of day, with or without food.
Tirzepatide is not a cure for obesity. When it is stopped, the appetite-suppressing and metabolic effects fade over several weeks as the drug clears, and weight tends to return. SURMOUNT-4 is the clearest evidence: people who lost about 21% on tirzepatide and were then switched to placebo regained 14% of their body weight within a year, while those who continued treatment kept losing weight. The SURMOUNT-1 prediabetes extension showed the same pattern, with weight and diabetes risk both beginning to rise within 17 weeks of stopping.
People stop for many reasons, including side effects, cost, insurance changes, supply problems, pregnancy plans and reaching a goal. There is no withdrawal syndrome and no medical need to taper. Some clinicians reduce the dose gradually to find the lowest dose that maintains weight, but this approach has not yet been tested in completed randomized trials, and research into maintenance strategies is ongoing.
Regain is not universal. Some people maintain much of their weight loss after stopping, particularly those who have built lasting changes in eating and physical activity. Regular weighing, continued resistance training, and a plan for what to do if weight starts to climb, including restarting treatment where appropriate, are the approaches most often recommended in obesity medicine guidance.
For people with diabetes, stopping tirzepatide usually means blood sugar rises again, so another glucose-lowering treatment typically needs to take its place. For people with sleep apnea, symptoms may return as weight returns, and a repeat sleep study may be needed. Anyone restarting after a gap of several weeks generally starts again at a lower dose rather than resuming the previous one, to reduce gastrointestinal side effects.
Type 2 diabetes in young people tends to progress faster than in adults, and treatment options have historically been limited. In February 2026, the FDA extended Mounjaro's approval to children aged 10 and older with type 2 diabetes, making tirzepatide the first dual GIP and GLP-1 medication approved for this group. The approved pediatric doses go up to 10 mg weekly.
The approval was based on SURPASS-PEDS, a trial of 99 young people aged 10 to 17 whose type 2 diabetes was not adequately controlled with metformin, basal insulin or both. After 30 weeks, HbA1c fell by 2.3 percentage points more on tirzepatide than on placebo, and 79% of those on tirzepatide reached an HbA1c below 6.5% compared with 29% on placebo. BMI fell by about 9% more than with placebo. Side effects were mainly gastrointestinal, mild to moderate and decreased over time, and no severe hypoglycemia was reported.
Zepbound is not approved for weight management in anyone under 18. Its label states that safety and effectiveness have not been established in pediatric patients. Trials of tirzepatide in adolescents with obesity are under way. Semaglutide (Wegovy) and liraglutide (Saxenda) are the GLP-1 medications currently approved for obesity in adolescents aged 12 and older.
Pediatric use raises questions that adult trials cannot answer, including effects on growth, puberty, bone development and eating behavior during a formative period, and what lifelong treatment would mean if the medication is needed indefinitely. The American Academy of Pediatrics recognizes medication as one option for adolescents with obesity, used alongside intensive lifestyle treatment, and the long-term data in young people are still being collected.
Head-to-head trials give the clearest comparison against semaglutide: tirzepatide has consistently produced statistically significant, clinically meaningful advantages in both blood sugar control and weight loss, with broadly similar side effect profiles dominated by the same GI symptoms. The most notable practical difference isn't about effectiveness at all — it's the oral contraceptive interaction discussed earlier, which requires specific counseling for tirzepatide but not semaglutide, making semaglutide a simpler choice for some women who rely on oral birth control. Compared to a different drug class entirely, SGLT2 inhibitors (like empagliflozin), the two aren't really competing for the same job. SGLT2 inhibitors have an exceptionally strong evidence base for reducing heart failure hospitalizations and slowing kidney disease progression, benefits so well established that they're now used even in people without diabetes. Tirzepatide's strength is superior blood sugar control and dramatically greater weight loss, with growing evidence for heart failure specifically in the obesity-linked HFpEF subtype. Rather than an either-or choice, current clinical guidelines increasingly support combining the two in people with multiple overlapping conditions — diabetes, obesity, and heart failure together, for example.
Soon after Mounjaro and Zepbound launched, demand exceeded supply, and the FDA placed tirzepatide on its drug shortage list in December 2022. Under U.S. law, compounding pharmacies may make copies of a commercially available drug when it is in shortage. Thousands of pharmacies and telehealth companies began selling compounded tirzepatide, usually at a much lower price than the brand-name product.
On October 2, 2024, the FDA announced that the shortage had been resolved. After a legal challenge from a compounding trade group, the agency reevaluated and confirmed that decision on December 19, 2024. It set end dates for compounding under the shortage exemptions: February 18, 2025 for state-licensed 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. After those dates, compounding essentially identical copies of tirzepatide is generally not permitted, except in narrow cases where a prescriber documents a clinical need for a meaningfully different formulation for an individual patient.
Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before they reach patients, and the agency has received reports of adverse events, including dosing errors when patients measured doses from multi-dose vials. It has also warned about products sold as research chemicals or labeled for research use only.
For people concerned about cost, Lilly now sells Zepbound single-dose vials directly at a lower cash price than pens, and insurance coverage varies widely by plan. Whether a particular compounded product is legal depends on the specific circumstances of its preparation and prescription, but none carries the manufacturing oversight, stability testing and batch control that come with an FDA-approved product.
Tirzepatide has a large evidence base for a relatively new medicine, with tens of thousands of trial participants and years of use by millions of people. Several important questions nonetheless remain open, and they matter for anyone weighing claims made about it.
The first is cardiovascular outcomes in people without diabetes. SURPASS-CVOT showed tirzepatide was at least as protective as dulaglutide in people with diabetes and heart disease, and semaglutide's SELECT trial showed a 20% reduction in cardiovascular events in people with obesity without diabetes. The equivalent tirzepatide trial, SURMOUNT-MMO, has not yet reported. The second is very long-term safety. The thyroid C-cell tumor warning is based on rodent studies, and human data so far have not shown a clear increase in thyroid cancer, but rare effects that take many years to appear cannot be ruled out by trials lasting three to four years.
The third is how best to maintain weight loss. Trials show regain after stopping, but it is not known whether lower doses, less frequent dosing or other strategies can maintain benefit with less medication. The fourth is who benefits most. Responses vary widely, from little weight loss to more than 30%, and there are no reliable ways yet to predict individual response in advance, although genetic and clinical predictors are being studied.
Finally, research is exploring effects beyond metabolism, including on kidney disease, knee osteoarthritis, alcohol and substance use, and psoriasis. Some of these findings are early, from small studies or observational data, and should be read as hypotheses rather than established benefits until randomized trials confirm them.
This guide draws on FDA prescribing information, peer-reviewed clinical trial publications, and clinical practice guidelines. It is provided for general education and does not constitute medical advice. Speak with a licensed healthcare provider about any medication or treatment decision.
FDA label for weight management and sleep apnea: warnings, side effect tables, dosing and storage.
FDA label for type 2 diabetes in adults and children aged 10 and older.
Tirzepatide as first-line monotherapy in type 2 diabetes versus placebo over 40 weeks.
Head-to-head trial of tirzepatide versus semaglutide 1 mg in type 2 diabetes.
Tirzepatide versus insulin degludec in type 2 diabetes treated with metformin.
Tirzepatide versus insulin glargine in type 2 diabetes with increased cardiovascular risk.
Tirzepatide added to insulin glargine in type 2 diabetes.
Cardiovascular outcomes with tirzepatide versus dulaglutide in 13,165 adults.
Tirzepatide in children and adolescents aged 10 to 17 with type 2 diabetes.
The main 72-week weight management trial in 2,539 adults without diabetes.
176-week results in adults with prediabetes, including diabetes prevention.
Weight management in adults with obesity and type 2 diabetes.
Tirzepatide after an intensive lifestyle intervention lead-in.
Randomized withdrawal trial of continued tirzepatide versus switch to placebo.
Head-to-head trial of tirzepatide versus semaglutide 2.4 mg in obesity.
Two trials of tirzepatide in obstructive sleep apnea with obesity.
Tirzepatide in heart failure with preserved ejection fraction and obesity.
Phase 2 trial of tirzepatide in MASH with liver fibrosis.
FDA announcement of the December 2024 Zepbound approval for sleep apnea.
FDA statement on the end of the tirzepatide shortage and compounding deadlines.
Both estimands for three-year weight loss and diabetes incidence after stopping.